Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Hepatology. 2023 Feb 23;78(1):295–306. doi: 10.1097/HEP.0000000000000324

Table 2.

Baseline demographic and laboratory data of alcohol-associated hepatitis cohorts confirmed dead or alive at 180 days included for mortality statistics.

n Total (n=37) New Cohort (n=10) Prior Cohort (n=27) P value
Gender (male), n 37 23 (62.2%) 6 (60.0%) 17 (63.0%) 1.000
Age (years) 37 50.0 [41.0;56.0] 51.1 [41.5;55.6] 50.0 [42.2;57.3] 0.837
BMI (kg/m2) 34 27.6 [24.1;31.7] 28.5 [26.1;36.7] 27.2 [23.1;31.3] 0.335
AST (IU/L) 37 136 [98.0;217] 190 [92.5;241] 128 [101;176] 0.505
ALT (IU/L) 37 48.0 [29.0;72.0] 60.5 [28.2;74.0] 48.0 [29.5;71.5] 0.905
GGT (IU/L) 20 130 [87.0;293] 143 [137;348] 120 [86.0;230] 0.432
AP (IU/L) 36 164 [124;232] 186 [165;233] 135 [117;225] 0.258
Bilirubin (mg/dL) 37 17.3 [9.95;20.5] 14.8 [7.02;19.7] 17.7 [10.9;21.0] 0.356
Albumin (g/dL) 34 2.40 [2.02;2.88] 2.45 [2.10;2.90] 2.35 [1.98;2.82] 0.623
INR 37 2.00 [1.70;2.50] 2.05 [1.82;2.45] 2.00 [1.65;2.48] 0.837
Creatinine (mg/dL) 37 0.99 [0.62;1.37] 0.99 [0.64;1.51] 0.99 [0.62;1.26] 0.771
Platelets (109/L) 35 115 [68.0;154] 83.5 [71.5;170] 123 [67.0;146] 0.913
MELD 37 25.6 [22.5;32.5] 27.4 [21.3;32.0] 25.3 [22.7;30.5] 0.824
FIB-4 35 9.47 [6.29;16.5] 9.48 [6.82;17.5] 9.47 [6.06;15.6] 0.884
FIB-4 > 3.25 (F3-F4), n 35 34 (97.1%) 9 (90.0%) 25 (100%) 0.286
Cytolysin positive, n 37 22 (59.5%) 3 (30.0%) 19 (70.4%) 0.056

Values are presented as median and interquartile range in brackets. The number of subjects for which data were available is indicated in the second column. Continuous variables were compared using the Mann-Whitney test. Categorical variables were compared using the Pearson’s Chi-squared test. Level for statistical significance is P<0.05. ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index; FIB-4, Fibrosis-4 Index; GGT, gamma-glutamyltransferase; INR, international normalized ratio; MELD, model for end-stage liver disease.